Immunitybio (IBRX) - Stock Price & Dividends

ImmunityBio, Inc. is a biotechnology company that focuses on developing therapies and vaccines to enhance the immune system's ability to combat cancers and infectious diseases. They are actively working in both the United States and Europe.

The company possesses a range of immunotherapy and cell therapy platforms, such as the antibody cytokine fusion protein N-803, vaccine technologies, toll-like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers, aiming to improve treatment outcomes.

ImmunityBio is currently advancing therapeutic agents through Phase II and III clinical trials targeting both liquid and solid tumors like bladder, pancreatic, and lung cancers. Additionally, they are working on combating pathogens such as SARS-CoV-2 and HIV, indicating a commitment to addressing varied health concerns.

With collaboration agreements in place with notable institutions like the National Cancer Institute and Amyris, Inc., and licensing agreements with various companies, ImmunityBio is actively engaging in partnerships to further their research and development efforts.

The company's headquarters are located in San Diego, California, which serves as the hub for their innovative work in the field of biotechnology. Visit their website at immunitybio.com to learn more about their groundbreaking initiatives.